X4 Pharmaceuticals Stifel 2026 Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Great. Welcome everyone to the next session here at the Healthcare Conference. Excited to be joined by X4 Pharmaceuticals. We have Executive Chairman Adam Craig, and interesting time for you guys. Maybe I was thinking we can kind of just start. Obviously, a lot has kind of gone on in terms of you guys coming in, kind of transforming the company. Maybe just kind of like set the stage of everything that's happened over maybe like the last year or so, and kind of what got you guys excited to join, and kind of what's the path forward from here?
Well, first of all, thank you for inviting us. We're pleased to be here. As David, CFO, who's with me today, David Kirske, and I have known about this company for three or four years ago. We looked at the company when we were at CTI BioPharma.
because we always thought mavorixafor was a good agent, an active agent, and an agent in which it could be developed successfully in chronic neutropenia.
About a year ago, the opportunity came along with a new investment that was made to work with some new investors and come into the company. In July of last year, and then in August, there was a refinancing and we joined as a new management team. We haven't been disappointed. Mavorixafor is what we thought it was.
Yeah. Once you get inside, you see the data.
We have spent the last year really sort of making the company more efficient, reducing costs. We've reduced headcount. We've changed the management team.
We've brought in some people outside with certain expertise. All that has led to us focusing on the enrollment of our pivotal phase III trial, the 4WARD trial.
Which is, as I've said repeatedly, is the main focus of the company that employees need to think every day, what are they doing towards that trial.
With that, we are looking forward to completing enrollment by the end of this year.
Then that would lead us to having topline data for the phase III in chronic neutropenia in the first quarter of 2028.
Awesome. On the trial, earlier this fall, you guys lowered the end slightly for the trial. Maybe just kind of talk about the decision to do that.
The trial when we joined, it was grossly overpowered.
The 176 patients, the powering of each of the primary endpoints was greater than 96%. We became confident that we were enrolling the correct patients.
The characteristics of the patients were correct, and that the patients were sick. This is something the FDA said to us, "You've got to enroll sick patients in whom you can show a difference.
When we saw that happening, we took another look at the sample size, and we saw that we could retain 89% powering for the infection endpoint and 93% powering for the ANC endpoint, if we took the sample down to size to 126. It really was for two reasons. One is it obviously makes good, it's prudent, it's good business sense not to over-enroll a trial. It's a double-blind, placebo-controlled trial, and I don't want to enroll more patients than we actually need Yeah to test the hypothesis.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
